European Union & Moderna

European Union: The European Union has provided critical medical supplies, including masks, gloves, boots, and medications, to aid the Ebola response in the Democratic Republic of the Congo.

Moderna: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.

European Union: The EU is reviewing mFLUSIVA, which could expand Moderna's market access.

Moderna: Moderna received its fourth FDA-approved product and first mRNA flu vaccine, boosting its commercial prospects and validating its mRNA platform.

European Union: The European Union considers the risk to its general public very low but has begun coordinating laboratory preparedness and traveler guidance through its Health Security Committee.

Moderna: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

European Union: A spokesperson for the European Union>>> stated that the risk of an Ebola outbreak in Europe is 'very low', indicating monitoring of the situation but no immediate alarm for the region.

Moderna: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.

European Union: Region where Palsonify received approval.

Moderna: Moderna is a partner with Vertex in developing CF treatments for patients not covered by Vertex's CFTR modulators. The acquisition does not directly affect Moderna.

Moderna: Moderna is another pharmaceutical company that entered into advance purchase agreements with the International — European Commission, also mentioned in the context of the secret vaccine deals.